학술논문

Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson's Disease: Final Results of a Phase 1b Study
Document Type
Journal
Source
NEUROLOGY; APR 14 2020, 94 15, 4p. Supplement: S
Subject
Language
English
ISSN
1526632X